Dextera Surgical (NASDAQ: DXTR) and Luminex (NASDAQ:LMNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.
Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.2%. Dextera Surgical does not pay a dividend. Luminex pays out 36.4% of its earnings in the form of a dividend.
This table compares Dextera Surgical and Luminex’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dextera Surgical||$3.42 million||0.70||-$17.22 million||($1.77)||-0.03|
|Luminex||$270.64 million||3.31||$13.81 million||$0.66||30.79|
Luminex has higher revenue and earnings than Dextera Surgical. Dextera Surgical is trading at a lower price-to-earnings ratio than Luminex, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
4.5% of Dextera Surgical shares are owned by institutional investors. Comparatively, 79.2% of Luminex shares are owned by institutional investors. 10.4% of Dextera Surgical shares are owned by company insiders. Comparatively, 6.9% of Luminex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Dextera Surgical and Luminex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for Dextera Surgical and Luminex, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Dextera Surgical presently has a consensus price target of $0.75, indicating a potential upside of 1,415.15%. Luminex has a consensus price target of $19.33, indicating a potential downside of 4.86%. Given Dextera Surgical’s stronger consensus rating and higher possible upside, analysts clearly believe Dextera Surgical is more favorable than Luminex.
Volatility & Risk
Dextera Surgical has a beta of -1.38, suggesting that its share price is 238% less volatile than the S&P 500. Comparatively, Luminex has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
Luminex beats Dextera Surgical on 10 of the 15 factors compared between the two stocks.
Dextera Surgical Company Profile
Dextera Surgical Inc., formerly Cardica, Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It designs, manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.
Luminex Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.
What are top analysts saying about Dextera Surgical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dextera Surgical and related companies.